Christoph Zielinski

Research interests

Publications

• Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

  Nature Medicine · 2023 · https://doi.org/10.1038/s41591-023-02321-8

• Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders

  Cancer Discovery · 2021 · https://doi.org/10.1158/2159-8290.cd-21-0538

• A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts

  The Lancet Haematology · 2018 · https://doi.org/10.1016/s2352-3026(18)30063-2

• Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients

  Journal of Thrombosis and Haemostasis · 2018 · https://doi.org/10.1111/jth.13951

• Global cancer control: responding to the growing burden, rising costs and inequalities in access

  ESMO Open · 2018 · https://doi.org/10.1136/esmoopen-2017-000285

• Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2017.73.6785

• Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases

  European Radiology · 2017 · https://doi.org/10.1007/s00330-016-4707-6

• Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2016 · https://doi.org/10.1200/jco.2016.67.6601

• Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers

  ESMO Open · 2016 · https://doi.org/10.1136/esmoopen-2015-000024

• Activity of T-DM1 in Her2-positive breast cancer brain metastases

  Clinical & Experimental Metastasis · 2015 · https://doi.org/10.1007/s10585-015-9740-3

• A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

  Annals of Oncology · 2015 · https://doi.org/10.1093/annonc/mdv249

• Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases

  OncoImmunology · 2015 · https://doi.org/10.1080/2162402x.2015.1057388

• Therapeutic vaccines for cancer: an overview of clinical trials

  Nature Reviews Clinical Oncology · 2014 · https://doi.org/10.1038/nrclinonc.2014.111

• Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma

  Neuro-Oncology · 2014 · https://doi.org/10.1093/neuonc/nou307

• Microparticle‐associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients

  Journal of Thrombosis and Haemostasis · 2012 · https://doi.org/10.1111/j.1538-7836.2012.04754.x

• Brain metastases: pathobiology and emerging targeted therapies

  Acta Neuropathologica · 2012 · https://doi.org/10.1007/s00401-011-0933-9

• High D-dimer levels are associated with poor prognosis in cancer patients

  Haematologica · 2012 · https://doi.org/10.3324/haematol.2011.054718

• Triple-negative breast cancer

  Wiener Medizinische Wochenschrift · 2010 · https://doi.org/10.1007/s10354-010-0773-6

• Prediction of venous thromboembolism in cancer patients

  Blood · 2010 · https://doi.org/10.1182/blood-2010-02-270116

• A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study

  Breast Cancer Research and Treatment · 2009 · https://doi.org/10.1007/s10549-009-0666-9

• D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study

  Journal of Clinical Oncology · 2009 · https://doi.org/10.1200/jco.2008.21.7752

• Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

  The Lancet · 2009 · https://doi.org/10.1016/s0140-6736(09)61497-5

• High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)

  Blood · 2008 · https://doi.org/10.1182/blood-2008-02-142422

• Capecitabine and Trastuzumab in Heavily Pretreated Metastatic Breast Cancer

  Journal of Clinical Oncology · 2007 · https://doi.org/10.1200/jco.2007.11.9776

• Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer

  Journal of Neuro-Oncology · 2007 · https://doi.org/10.1007/s11060-007-9420-5

Current projects

No projects listed.